---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-003940"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T02:48:06.575963+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Intellia Q4 net loss $113.4M, cash $1.3B; NTLA-2002 Phase 2 started, NTLA-2001 pivotal plan on track

## Summary
- Q4 2022 net loss $113.4M vs $81.2M YoY; R&D expenses rose to $100.0M from $71.2M.
- Cash, equivalents and marketable securities $1.3B as of Dec 31, 2022, up from $1.1B.
- Initiated global Phase 2 study of NTLA-2002 for HAE; submitted IND to FDA for U.S. enrollment.
- Plan to submit IND for NTLA-2001 in ATTR-CM in mid-2023; global pivotal trial expected by year-end 2023.
- IND-enabling activities for NTLA-3001 (AATD lung) with filing planned in 2H 2023.

## SEC filing metadata
- accession: 0000950170-23-003940
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000095017023003940/0000950170-23-003940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000095017023003940/ntla-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-003940
- JSON: https://secwatch.observer/filing/0000950170-23-003940.json
- Plain text: https://secwatch.observer/filing/0000950170-23-003940.txt

## Key facts
- Earnings Releases
  Intellia Therapeutics, Inc. reported financial results for quarter and year ended December 31, 2022.
  - Period: quarter and year ended December 31, 2022
  - Result: reported results
  source text: On February 23, 2023, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000095017023003940/0000950170-23-003940-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.